KATRD
LOGIN
- KATRD 2021 International Conference
-
November 7(Thu)-8(Fri), 2020 Lotte Hotel World, Seoul, Kore
Program in Detail
|
Oral Presentation 16 Lung Cancer 1 |
12:50-13:30 |
||
|---|---|---|---|
| Chair | |||
| 10:30-10:40 | OP 16-1 |
microRNA-26a-5p Regulates the Cancer stemness and Enhances the Chemosensitivity of Lung Adenocarcinoma
|
|
| 10:40-10:50 | OP 16-2 |
Heterogeneous Radiological Response to Chemotherapy is Associated with Poor Prognosis in Advanced Non-small-cell Lung Cancer
|
|
| 10:50-11:00 | OP 16-3 |
Clinical Significance of Advanced Lung Cancer Inflammation Index in Limited Disease Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
|
|
| 11:00-11:10 | OP 16-4 |
Impaired Lung Function and Lung Cancer Incidence: A Nationwide Population-based Cohort Study
|
|
| 11:10-11:20 | OP 16-5 |
Blood-based Biomarker Analysis for Predicting Efficacy of Definitive Concurrent Chemoradiotherapy and Durvalumab Consolidation in Patients with Unresectable Locally Advanced Non-small Cell Lung Cancer
|
|
| 11:20-11:30 | OP 16-6 |
Clinical Usefulness of Serum KL-6 Test for Predicting Occurrence and Assessing Severity of Treatment-related Interstitial Lung Disease in Lung Cancer: A Single Center Cohort Study
|
|
| 11:30-11:40 | OP 16-7 |
Association between Clinical Parameters and Resectability in Stage III Non-small Cell Lung Cancer
|
|
| 11:40-11:50 | OP 16-8 |
Tri-iodothyronine (T3) as a Prognostic Factor for Patients with Advanced Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
|
|
| 11:50-12:00 | OP 16-9 |
Digital Aging and Mental Health Deteriorations: Risk Mitigation in the Older People with Lung Cancer Disease in Indonesia
|
|
|
Oral Presentation 17 Lung Cancer 2 |
13:30-14:20 |
||
| Chair | |||
| 13:30-13:40 | OP 17-1 |
High Tumor Mutation Burden Predicts Unfavorable Clinical Outcomes in EGFR-mutated Lung Adenocarcinoma Treated with Targeted Therapy
|
|
| 13:40-13:50 | OP 17-2 |
GDF-15 Levels Predict Efficacy in Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors
|
|
| 13:50-14:00 | OP 17-3 |
Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-dose CT Screening
|
|
| 14:00-14:10 | OP 17-4 |
Comparison of Clinical Characteristics and Prognosis of Incidentally Detected and Screening Detected Lung Cancers
|
|
| 14:10-14:20 | OP 17-5 |
Incidence and Risk Factors for Brain Metastasis in Patients with Presumed Early-stage Lung Cancer
|
|
| 14:20-14:30 | OP 17-6 |
Association Between Quality of Life Questionnaire at Diagnosis and Survival in Patients with Lung Cancer
|
|
| 14:30-14:40 | OP 17-7 |
Clinical Factors Associated with Circulating Tumor DNA Detection in Chronic Obstructive Pulmonary Disease Patients with Lung Cancer
|
|
| 14:40-14:50 | OP 17-8 |
Semi-supervised Deep Learning Extraction for Information of Lung Cancer Staging from Unstructured Reports of PET-CT Interpretation
|
|
| 14:50-15:00 | OP 17-9 |
Machine Learning Classification of Bronchogenic Carcinoma based on Fuzzy Logic
|
|
|
Oral Presentation 18 Lung Cancer 3 |
14:20-15:00 |
||
| Chair | |||
| 15:30-15:40 | OP 18-1 |
Effects of Developed Chronic Pulmonary Aspergillosis after Lung Cancer Surgery on Mortality and Lung Function Decline
|
|
| 15:40-15:50 | OP 18-2 |
Efficacy of Local Radiotherapy or Metastasectomy in Stage IV NSCLC with Single Extrathoracic Metastasis: Evaluation of Nationwide Korean Lung Cancer Populations
|
|
| 15:50-16:00 | OP 18-3 |
Predictability of Prior Radiotherapy and Immunotherapy-related Adverse Effects for Outcomes in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy
|
|
| 16:00-16:10 | OP 18-4 |
The Role of 6-minute Walk Test and Cardiopulmonary Exercise Test in Early-stage Lung Cancer Patients with Reduced Pulmonary Function
|
|
| 16:10-16:20 | OP 18-5 |
Association of Diagnostic Lung Biopsy on the Risk of Spread Through Air Spaces (STAS) and Its Prognostic Impact in Resected Stage I Non-Small Cell Lung Cancer (NSCLC)
|
|
| 16:20-16:30 | OP 18-6 |
Comparison of Clinical Stage and Pathologic Stage in Patients with Non-small Cell Lung Cancer
|
|
| 16:30-16:40 | OP 18-7 |
Real-world Experience on the Use of Durvalumab after Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer
|
|
| 16:40-16:50 | OP 18-8 |
A Propensity-matched Real-world Data Analysis of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer
|
|
| 16:50-17:00 | OP 18-9 |
Stereotactic Body Radiation Therapy in Stage I Non-small Cell Lung Cancer Patients with Peripheral Tumors in Vietnam
|
|